Studies report patients lose an average of 1-2 pounds weekly once reaching maintenance doses
Semaglutide, when used in combination with other medications, may raise the risk of developing low blood sugar levels or hypoglycemia
Journal of Allergy and Clinical Immunology Practice, 11(3), 789-798
Notably, the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial, the first dedicated kidney outcome trial evaluating canagliflozin in people with type 2 diabetes mellitus and CKD, demonstrated a substantial reduction in the risk of kidney events [46]
Standard-dose semaglutide may be a good fit for patients who want meaningful weight loss support, prefer a GLP-1-only pathway, are comfortable with gradual titration, and want a balance of effectiveness and tolerability
Social eating dynamics change